Downstream Process Development in Biotechnology: Advances in Bioprocessing #bioprocessing

Down Stream
6 followers
5 Video Views·Jun 10, 2026
Biopharmaceutical downstream processing (DSP) refers to the recovery and purification of a drug substance (DS) from natural sources, such as animal or bacterial cells. Downstream processing in biotechnology is applicable in mAb or protein processes, as well as in the manufacture of oligonucleotides, polysaccharides, and various vaccines.
AI Generated·May contain errors
Video Summary
AI GeneratedModern bioprocessing has seen significant upstream advancements in cell line development and biomass density, making large molecule production economically feasible. However, these improvements have created severe bottlenecks in legacy downstream operations, leading to yield losses and process inefficiencies that now require targeted technological investments and PAT integration.
In order to make biological molecules economically and process feasible,
improvements were needed to historical cell culture production methods.
Biomass and titer levels had to increase significantly, but new methods of control
were also needed. Methods such as genetic modification of organisms capable of producing
more and high quality drug substance, improved controls of cell culture feedstocks and metabolite
byproducts, and finally a combination of methods which increased total cell density or TCD,
or total biomasses, as well as high viable cell densities or BCD. Downstream operations
were not historically given focus as capacity and efficiency was still historically appropriate.
As we can observe around us today, historical investment in upstream cell line development,
metabolite feed controls, biomass improvements, and product output per biomass have collectively
made large molecule bioprocesses economically and engineering feasible. The consequence of
such modernization and upstream improvement has now placed new burdens and bottlenecks on most
legacy downstream operations. Even while performing the perfect downstream unit operation,
there will have inherent compounding and yield loss and process inefficiencies which are
significant. Even with 95% yield at each unit operation, there is a fundamental loss due to
things like line dead volumes, centrifugation losses and tie up on filters, chromatography
impurities, fraction cuts and separations, agglomeration, aggregation, and stability issues,
sampling methods and measurement induced errors, and bottlenecks are prevalent in every unit
operation. Many of the common bottlenecks include areas around harvest, high cell masses and
debris, and the variable particle conditions at the end, buffer usage or excessive consumption
concerns, point of use preparation, storage instability, and floor space occupancy,
simultaneous excipient tracking and verification, in many cases it's actually common to lose sight
of many process conditions with multiple excipients, water usage, high consumption
of distilled water or whiffy, and other infrastructure limitations and burdens,
issues around wide tolerances of drug substance concentration, commonly or typically seen around
plus or minus 5% in many cases, undesirable or unexplained process variability such as on
different days, different results, or conditions where we just don't simply have the means to
correlate process events, unacceptably high batch failure rates or root cause investigations which
are not supported by methods situated to in-situ processes, batch comparison and other data capture
and data structuring methods as well. The upstream improvements and new challenges
imposed on downstream bioprocessing have put new focus on downstream improvements and investments.
To address drivers such as process quality and consistency, resource management and cost and
yield improvements, PAT needs to provide several things, including dynamic range improvements,
precision and accuracy improvements, reducing the number of sampling errors,
sample handling, and results delay, process intensification, including integration,
connected, continuous, and modular PAT, which can also help support reduced cycle times and
material handling. Also providing in-situ particle system characterization and tracking,
providing advanced buffer management, and reducing unnecessary consumption of buffers,
as well as aiding in point-of-use creation. Component and excipient identification and
tracking as well, and finally documentation standardization,
peripheral processes communication, data capture, and even structured data.
